FDA Gives Pharmacists Thumbs Up for Paxlovid Prescribing
(MedPage Today) -- Licensed pharmacists can now prescribe nirmatrelvir-ritonavir (Paxlovid) for COVID-19 patients at high risk of progressing to severe disease (though with some limitations), the FDA announced on Wednesday.
"Since Paxlovid must... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - July 6, 2022 Category: Infectious Diseases Source Type: news
' Important' New Data on Second-Line HIV Treatment Regimens: The NADIA Study'Important' New Data on Second-Line HIV Treatment Regimens: The NADIA Study
For second-line HIV therapy, both dolutegravir and ritonavir-boosted darunavir regimens, plus two nucleoside reverse-transcriptase inhibitors (NRTIs), maintained good viral suppression during 96 weeks follow-up in the NADIA trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2022 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news
Bad news for Paxlovid? Coronavirus can find multiple ways to evade COVID-19 drug
Prescriptions for Pfizer’s blockbuster drug Paxlovid have skyrocketed in recent weeks. That’s good news for many COVID-19 patients, as the pill has been proven to reduce severe disease from SARS-CoV-2 infections. But a bevy of new lab studies shows the coronavirus can mutate in ways that make it less susceptible to the drug, by far the most widely used of the two oral antiviral drugs authorized to treat COVID-19 in the United States. Researchers have found some of those mutations in variants already circulating in infected people, raising fresh concerns that physicians could soon lose one of their best therapies for fi...
Source: ScienceNOW - June 29, 2022 Category: Science Source Type: news
Fauci's Paxlovid Rebound; Elmo Gets a COVID Jab; BA.4, BA.5 Now Dominant in U.S.
(MedPage Today) -- Note that some links may require registration or subscription.
White House chief medical advisor Anthony Fauci, MD, says he is experiencing rebound COVID symptoms following a course of nirmatrelvir-ritonavir (Paxlovid). (Daily... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 29, 2022 Category: American Health Source Type: news
Rebound of COVID-19 Symptoms Rare After Nirmatrelvir/Ritonavir Treatment
THURSDAY, June 16, 2022 -- Few patients experience rebound of COVID-19 symptoms after nirmatrelvir/ritonavir (NM/R) treatment, according to research published online June 14 in Clinical Infectious Diseases.
Nischal Ranganath, M.D., Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 16, 2022 Category: Pharmaceuticals Source Type: news
Paxlovid Misses in Standard-Risk COVID-19
(MedPage Today) -- Updated findings from a nirmatrelvir/ritonavir (Paxlovid) trial in standard-risk COVID-19 suggest the antiviral's benefits are less clear for those not at high risk of severe outcomes.
As was previously reported, Pfizer's so... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 15, 2022 Category: American Health Source Type: news
Paxlovid Rebound Incidence Low, Study Suggests
(MedPage Today) -- Only a very small number of high-risk patients with COVID-19 experienced "rebound symptoms" after being treated with nirmatrelvir/ritonavir (Paxlovid), a retrospective study found.
Among nearly 500 patients, 93% of whom were... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 14, 2022 Category: American Health Source Type: news
Cipla, DNDi launch 4-in-1 antiretroviral treatment for children with HIV
South African Health Products Regulatory Authority (SAHPRA) has approved the sweet-tasting, heat-stable and '4-in-1' fixed-dose combination of four antiretroviral (ARV) treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV, Cipla said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 14, 2022 Category: Pharmaceuticals Source Type: news
Study finds few COVID-19 patients get rebound symptoms after Paxlovid treatment
ROCHESTER, Minn. — Mayo Clinic researchers studied the outcomes of 483 high-risk patients treated for COVID-19 with a five-day oral regimen of nirmatrelvir and ritonavir, together marketed as Paxlovid. Only a handful developed COVID-19 rebound symptoms, and the researchers say more studies are needed to determin e why. Overall, the treatment benefited everyone in the study. All recovered, including the patients who developed rebound symptoms, which were generally mild. The findings appear in the journal Clinical… (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - June 14, 2022 Category: Hospital Management Source Type: news
Pfizer to invest $120 million to produce COVID-19 oral treatment in the U.S.
Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). The investment will expand the production of active pharmaceutical ingredient (API) and registered starting materials (RSMs) used in the manufacture of nirmatrelvir, a novel main protease (Mpro) inhibitor originating in Pfizer's laboratories, which will create more than 250 additional high-skilled...
Source: World Pharma News - June 8, 2022 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Paxlovid COVID Rebound: No Evidence for More Treatment, Says CDC
(MedPage Today) -- No evidence exists to support an additional course of treatment in patients with COVID-19 who experience a recurrence in illness after taking nirmatrelvir/ritonavir (Paxlovid), the CDC said on Tuesday.
In a Health Advisory... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 24, 2022 Category: American Health Source Type: news
Experts Attempt to Demystify Paxlovid Prescribing
(MedPage Today) -- Nirmatrelvir/ritonavir (Paxlovid) may interact with a number of medications, but that does not mean doctors should shy away from prescribing it, Infectious Diseases Society of America (IDSA) experts said during a press call on... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 20, 2022 Category: American Health Source Type: news
Caution Urged With Paxlovid in Transplant Patients
(MedPage Today) -- Solid organ transplant recipients prescribed nirmatrelvir/ritonavir (Paxlovid) for COVID-19 should have their immunosuppressive drugs held and medication concentrations checked, and should undergo drug monitoring every 2 weeks... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - May 13, 2022 Category: Infectious Diseases Source Type: news
What Paxlovid Rebound Could Mean for Patients
(MedPage Today) -- In this video, Michael Mina, MD, PhD, formerly an epidemiologist at Harvard and now chief science officer of eMed, discusses the cause of viral rebound with ritonavir/nirmatrelvir (Paxlovid), what it could mean for the evolution... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 13, 2022 Category: American Health Source Type: news
Here ’s What You Need to Know About Paxlovid
Prescriptions for Pfizer’s COVID-19 antiviral medication Paxlovid—the first such pill to be authorized by the U.S. Food and Drug Administration (FDA)—have increased tenfold in the past two months. Between late February and April 22, the number of patients using Paxlovid jumped from 8,000 to 80,000, according to Pfizer CEO Albert Bourla; the drug is now available at some 33,000 locations, such as pharmacies and outpatient clinics, across the country.
On April 26, the White House announced it would step up its efforts to encourage more doctors to prescribe the antiviral medication. As part of this, the Bide...
Source: TIME: Health - May 9, 2022 Category: Consumer Health News Authors: Kyla Mandel Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
